Rein Therapeutics Inc.
RNTX
$1.76
-$0.15-7.85%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -53.56% | 20.15% | 179.87% | 71.73% | 131.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.61% | 207.08% | 334.57% | 80.62% | 55.26% |
| Operating Income | 20.61% | -207.08% | -334.57% | -80.62% | -55.26% |
| Income Before Tax | -479.44% | -220.03% | -400.39% | -48.84% | -61.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -458.40% | -220.03% | -400.39% | -48.84% | -61.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -458.40% | -220.03% | -400.39% | -48.84% | -61.40% |
| EBIT | 20.61% | -207.08% | -334.57% | -80.62% | -55.26% |
| EBITDA | 20.04% | -208.96% | -336.90% | -81.09% | -55.58% |
| EPS Basic | -22.77% | 32.91% | -14.13% | 18.59% | -53.67% |
| Normalized Basic EPS | 83.50% | 32.68% | -8.76% | -3.56% | -54.14% |
| EPS Diluted | -22.77% | 32.91% | -14.13% | 18.59% | -53.67% |
| Normalized Diluted EPS | 83.50% | 32.68% | -8.76% | -3.56% | -54.14% |
| Average Basic Shares Outstanding | 354.83% | 377.03% | 338.46% | 82.81% | 5.03% |
| Average Diluted Shares Outstanding | 354.83% | 377.03% | 338.46% | 82.81% | 5.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |